Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant 3DCRT/IMRT in Combination With Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial

NCT00528866 is registered in ClinicalTrials.gov with Radiation Therapy Oncology Group as lead sponsor.

NCT NCT00528866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00528866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant 3DCRT/IMRT in Combination With Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial
Lead sponsor
Radiation Therapy Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
May 14, 2018
Enrollment
80 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer